Berenberg initiated coverage of Haleon plc with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | Buy → Neutral | Goldman | |
| 8/6/2024 | Buy | Berenberg | |
| 6/5/2024 | Buy | Berenberg | |
| 4/17/2024 | Buy | HSBC Securities | |
| 12/11/2023 | Buy | Jefferies | |
| 11/1/2023 | $9.00 | Overweight | Morgan Stanley |
| 5/24/2023 | Hold | Stifel | |
| 4/6/2023 | $10.00 | Hold → Buy | Argus |
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
BOSTON, June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (NYSE:HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company. Suave Brands Company Chief Executive Officer, Daniel Alter, said, "As we continue to build Suave Brands Company as the top independent North American beauty & personal care company by combining the agility of a start-up with the power of market leading brands, the addition of Cha
BOSTON, Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (NYSE:HLN), a global leader in consumer health. The transaction is intended to close in the first half of 2024 upon completion of customary closing and regulatory approvals. ChapStick invented the lip care category in the 1880s with the launch of a now-iconic lip balm that made ChapStick a household name. For more than a century, ChapStick has added products to its portfolio with innovative new i
Not for release, publication or distribution, directly or indirectly, in or into any jurisdiction into which such distribution would be unlawful. This notice is for informational purposes only and does not constitute an offer to purchase, or a solicitation of an offer to sell, any securities. The exchange offers referred to herein are being made solely pursuant to the Prospectus and related documents. The exchange offers referred to herein are not being made to holders of securities in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. LONDON, Oct. 31, 2022 /PRNewswire/ -- Haleon plc ("Haleon
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
Goldman downgraded Haleon plc from Buy to Neutral
Berenberg initiated coverage of Haleon plc with a rating of Buy
Berenberg initiated coverage of Haleon plc with a rating of Buy
The new campaign features Canadian NFL Player Chase Brown of the Cincinnati Bengals MISSISSAUGA, ON, Oct. 15, 2024 /CNW/ - Today, Advil proudly announced it is the official pain relief partner of the NFL in Canada. Recognizing that tough pain can slow anyone down, this partnership highlights the fast-acting relief of Advil alongside the excitement of the NFL. The campaign features Chase Brown, the speedy running back from London, Ontario, who plays for the Cincinnati Bengals. https://www.youtube.com/watch?v=bn5jduq2qNI "Advil is excited to bring this campaign to Canadians as we continue to help them tackle their pain" said Amrita Maharajh, Senior Brand Manager, Advil. The campaign will off
LONDON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PubMatic (NASDAQ:PUBM), an independent technology company delivering digital advertising's supply chain of the future, today announced the launch of a new collaborative approach to supply path optimisation (SPO) for global healthcare company, Haleon. PubMatic has been selected by Haleon as a preferred supply partner to increase efficiency and streamline access to video, display, and connected TV (CTV) inventory globally, while also making media investments more sustainable. PubMatic provides transparent bidding technology and actively supports Haleon brands including Advil, Centrum, and Tums through programmatic media buys, thus maximising effici
Eroxon® is Haleon's first offering in the sexual health spaceClinical studies show Eroxon® is safe and effective in men with EDEroxon® is available now for Amazon pre-order; available on shelves and online at most major retailers in October 2024WARREN, N.J., Sept. 3, 2024 /PRNewswire/ -- Eroxon®, the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024. Eroxon® is clinically proven to help me
On Wednesday, Haleon plc (NYSE:HLN) agreed to sell its nicotine replacement therapy business outside of the U.S. to Dr. Reddy's Laboratories SA, a wholly owned subsidiary of Dr. Reddy's Laboratories Limited (NYSE:RDY) for 500 million pounds (around $632 million). The nicotine replacement therapy (NRT) portfolio consists of brands such as Nicotinell, Nicabate, Habitrol, and Thrive, which are available in gum, lozenge, and patch forms across over 30 markets. The 500 million pound consideration is structured as an upfront cash payment of 458 million pounds, with a further up to 42 million pounds deferred performance-based consideration payable during 2025 and H1 2026. The transaction
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United StatesAcquisition seen as ideal anchor to continue to build the company's global consumer healthcare OTC businessIn recent years, Dr. Reddy's has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé IndiaDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), a global pharmaceutical company, today announced that its subsidiary Dr. Re